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Background and Aims: Clinical trial data have indicated an association between wholegrain 3 
consumption and a reduction in surrogate markers of cardiovascular disease. Phenolics present in 4 
wholegrain bound to arabinoxylan fibre may contribute these effects, particularly when released 5 
enzymatically from the fiber prior to ingestion. The aim of the present study was therefore to 6 
determine whether the intake of high fibre bread containing higher free ferulic acid (FA) levels 7 
(enzymatically released during processing) enhances human endothelium-dependent vascular 8 
function. 9 
Methods:  A randomized, single masked, controlled, crossover, human intervention study was 10 
conducted on 19 healthy men. Individuals consumed either a high fibre flatbread with enzymatically 11 
released free FA (14.22 mg), an equivalent standard high fibre bread (2.34 mg), or a white bread 12 
control (0.48 mg) and markers of vascular function and plasma phenolic acid concentrations were 13 
measured at baseline, 2, 5 and 7 hours post consumption. 14 
Results:  Significantly increased brachial arterial dilation was observed following consumption of 15 
the high free FA (‘enzyme-treated’) high fibre bread verses both a white flatbread (2h: p<0.05; 5h: 16 
p<0.01) and a standard high fibre flatbread (5h: p<0.05). Concurrently, significant increases in 17 
plasma FA levels were observed, at 2 h (p<0.01) after consumption of the enzyme-treated flatbread, 18 
relative to control treatments. Blood pressure, heart rate, DVP-SI and DVP-RI were not 19 
significantly altered following intake of any of the breads (p>0.05).   20 
Conclusion:  Dietary intake of bread, processed enzymatically to release FA from arabinoxylan 21 
fiber during production increases the bioavailability of FA, and induces acute endothelium-22 
dependent vasodilation.  23 
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Clinical data suggest that the regular intake of foods/beverages rich in phenolic compounds, such as 29 
cocoa, green tea, and berries, improves human vascular function and maintains a healthy circulatory 30 
function [1-4]. However, such foods/beverages tend to be expensive, have limited availability and 31 
are not consumed by large proportions of the population.  Thus, to increase the intake of phenolic 32 
compounds at the population level, in a sustainable, economically viable way, requires their 33 
delivery through foods derived from staple crops such as rice, maize and wheat.  Wholegrain wheat 34 
is a rich source of phenolic acids, in particular ferulic acid (FA) [5,6], in addition to vitamins, 35 
minerals, phytosterols, unsaturated fatty acids and lignans [7,8], and is consumed as both white and 36 
wholemeal breads and other cereal products.  There is robust scientific evidence that diets rich in 37 
wholegrain have a beneficial effect on cardiovascular health [9-12] and current dietary guidelines 38 
emphasize the importance of wholegrain in the diet [13]. 39 
A number of components of wheat have been suggested to contribute to the cardiovascular health 40 
benefits associated with wholegrain consumption, most notably the fiber component [6,11,14,15].  41 
However, phenolic compounds that are bound to arabinoxylan fibre, particularly the 42 
hydroxycinnamate FA, may also contribute, in part, to vascular health effects [16-18]. FA 43 
comprises up to 90 % of the phenolic acids present in wholegrain wheat and is concentrated in the 44 
outer and aleurone layers of the grain (the bran) where it is present in three forms: as soluble free 45 
acid, soluble conjugates, and insoluble bound forms [6,19]. The latter constitute the majority of FA, 46 
and is covalently linked to arabinoxylan polysaccharides via stable ester bonds. Bound FA may also 47 
act as structural cross-links in cell walls, by oxidative dimerization [20].  Although cleavage of the 48 
ester linkage to release free FA is possible in the colon via fecal microbial xylanases and esterases, 49 
it is estimated that only about 25% of bound FA is released during this phase of digestion [21-24]. 50 
Consequently, its liberation and absorption in the gastrointestinal tract and potential to induce 51 
beneficial vascular changes in humans is limited, although slow release and absorption of phenolic 52 




In the present study, we produced high fibre bread with high amounts of free FA, released 54 
enzymatically during dough development, in order to determine whether dietary-relevant amounts 55 
of free FA delivered in high fibre bread are capable of inducing acute beneficial effects upon 56 
endothelial function.   57 
SUBJECTS AND METHODS 58 
Production and composition of breads 59 
Triticum aestivum cv Hereward was grown at Rothamsted Research (Harpenden, UK) and milled by 60 
Campden BRI (Chipping Campden, UK) using a Buhler MLU-202 mill (Urzwil, Switzerland) to 61 
give 10 fractions; Reduction 1 (R1), Reduction 2 (R2), Reduction 3 (R3), Break 1 (B1), Break 2 62 
(B2), Break 3 (B3), Bran Flour (BF), Offal Flour (OF), Bran Off-tails (BO) and Offal Off-tails 63 
(OOT). Selected fractions were combined to produce experimental unleavened breads: white flour 64 
was prepared by combining breaks 1, 2 and 3 and reductions 1, 2 and 3 with an extraction rate of 65 
72.0% of total flour.  ‘High fibre’ flour was prepared by combining 9 fractions: breaks 1, 2 and 3, 66 
reductions 1, 2 and 3, bran flour, offal flour, and offal off tails with an extraction rate of 85% of 67 
total flour. The bran off-tails were not included in the ‘high fibre’ flour as their coarse texture 68 
reduced the palatability of the breads. The FA content of the milled wheat fractions is shown in 69 
Supplemental data, Table S1. Intervention breads (unleavened, flatbreads) were produced by 70 
combining flour, water, enzyme (Ultraflo L®) and salt (Table 1) for 5 min using a Buhler mixer. 71 
Ultraflo L®, a commercial -glucanase, which also possesses xylanase and feruloyl esterase 72 
activities, was used to release FA bound to arabinoxylan. For the breads used in the intervention 73 
study this enzyme mixture was diluted in water at a ratio of 95:5 (water:Ultraflo L® , (v/v) ). Dough 74 
was made using flour, water (containing the 5% enzyme solution) and salt in the following 75 
proportions 60.5% flour; 38.7% water; 0.7% salt. The dough was left to prove for 4 hours in a 76 
temperature-controlled environment (20oC), before being divided into 50 g portions and rolled to 13 77 




 The control breads (white and high fibre) contained deactivated Ultraflo L® (95°C for 30 minutes, 79 
then cooled on ice).   80 
 81 
The white intervention bread differed in appearance to the high fiber breads due to the flours used 82 
in each, although there were no observable differences between the standard and enzyme-treated 83 
high fibre breads. The optimum conditions for enzymatic release of FA from arabinoxylan during 84 
dough proving were established prior to the production of breads for intervention (Supplementary 85 
Figures 2A and 2B). All breads were made at the same time and stored at -20°C until use.  No 86 
significant degradation of FA was observed within breads following 2 or 4 weeks of storage at -87 
20°C (p>0.05) (data not shown).  88 
 89 
Phenolic acids present in the original milling fractions (n=3) (Supplementary Table S1) and in the 90 
final intervention breads (n =3) (Table 1) were quantified as described by [6]. Briefly, after addition 91 
of an internal standard free phenolic acids were extracted from finely ground material in 80% (v/v) 92 
ethanol. Bound phenolics were determined in samples after the removal of free and conjugated 93 
phenolic acids. Internal standard was added to the remaining residue and 2M NaOH added to 94 
release the esterified phenolic acids. Following centrifugation, the supernatant was acidified with 95 
12M HCl, mixed thoroughly, ethyl acetate added, mixed and centrifuged again. The upper phase 96 
was removed, and the ethyl acetate extraction repeated a further two times. The combined 97 
supernatants are evaporated to dryness in a Speedvac. The dry sample was then re-suspended in 2% 98 
(v/v) acetic acid, centrifuged and FA levels quantified using an Agilent 1100 HPLC equipped with a 99 
diode array detector (as described by [6], using authentic standards and an internal standard (3,5-100 
Dichloro-4-hydroxybenzoic acid).  All fractions were dried prior to re-suspension in 2% (v/v) acetic 101 
acid. 50 l of each extract was separated using a Discovery RP-Amide C16 column (250 x4.6mm, 102 
5m) maintained at 30°C.  The mobile phases consisted of a mixture of acetonitrile (solution A) 103 




gradient system was used (min/% B): 0/100, 30/85, 50/50, 70/30, with 10 min post-run for column 105 
re-equilibration. The wavelength used for quantification of FA was 280 nm and spectral 106 
characteristics were scanned over the range 200–600 nm. All data were analyzed using 107 
ChemStation software.  108 
Ethics 109 
The clinical trial was registered at clinicaltrials.gov (NCT03946293) and conducted according to 110 
the Declaration of Helsinki following Good Clinical Practice (GCP) and was approved for conduct 111 
by the University of Reading’s Research Ethics Committee (ethics reference number 12/06). All 112 
volunteers signed an informed consent form before commencing the study. 113 
Intervention study population 114 
Healthy male volunteers (n = 19) (Figure 1) were recruited from the University of Reading and 115 
surrounding areas by use of the Hugh Sinclair Unit volunteer database, poster advertisement within 116 
the university and local community via local websites.  Volunteers were screened and selected 117 
according to the following inclusion criteria: 1) fasting lipids in the upper half of the normal range 118 
(triacylglycerol 0.8-3.2 mmol/l and total cholesterol 6.0-8.0 mmol/l); 2) BMI 25-32 kg/m2; 3) non-119 
smoker; 4) not diabetic (diagnosed or fasting glucose < 7 mmol/l) or suffer from endocrine 120 
disorders; 5) hemoglobin and liver enzymes levels within the normal range [Alanine Transaminase 121 
(ALT): 0-55 IU/L; Alkaline Phosphatase  (ALP): 38-126 U/L; Aspartate Transaminase (AST): 0-45 122 
IU/L; Gamma Glutamyl Transferase (GGT): 12-58 IU/L]); 6) not having suffered a myocardial 123 
infarction/stroke in the past 12 months; 7) not suffering from renal or bowel disease or have a 124 
history of choleostatic liver or pancreatitis; 8) not on drug treatment for hyperlipidemia, 125 
hypertension, inflammation or hyper-coagulation; 9) not taking any fish oil, fatty acid or vitamin 126 
and mineral supplements; 10) no history of alcohol misuse; 11) not planning, or on a weight 127 
reduction regime; 12) not having taken antibiotics in the 6 months prior to the study; and 13) being 128 




not to alter their usual dietary or fluid intake, with respect to amount consumed.  Volunteers were 130 
requested to refrain from the following, 24 h prior to, and during, the study visits: 1) consumption 131 
of polyphenol-rich foods including fruits, vegetables, wholegrain bread/pasta/rice, cocoa, coffee, tea 132 
and wine; 2) participating in vigorous exercise (> 3 x 20 min/week); and 3) consuming more than 133 
168 g of alcohol (any form) per week.  Volunteers were further asked to fast for 12 hours before 134 
each study visit and during that period only consume low-nitrate water provided. The Baseline 135 
characteristics of the study population are presented in Table 1. 136 
Study design 137 
The study was a randomized, single blind, crossover, controlled intervention trial in which subjects 138 
attended the Hugh Sinclair Unit of Human Nutrition on 3 separate occasions. We considered the 139 
trial to be single blinded (researcher) as interventions differed slightly in appearance, although no 140 
information regarding the interventions could be implied from this.  Visits were separated by at 141 
least 2 weeks, and treatments to subjects were allocated randomly using a restricted Williams 142 
design (as patients were recruited sequentially) by an independent researcher, who implemented the 143 
allocation sequence on the first visit. On arrival, subjects were rested in the supine position for at 144 
least 30 minutes in a quiet, air-conditioned environment (22-24°C), during which time they were 145 
cannulated for venous blood collection and baseline vascular measurements were taken, including 146 
FMD of the brachial artery (primary outcome), laser Doppler imaging (LDI) with iontophoresis, 147 
and digital pulse wave (DVP), and systolic and diastolic blood pressure (Omron MX2 automatic 148 
digital upper arm blood pressure monitor).  Following collection of baseline measurements, 149 
volunteers were requested to consume three 30 g flatbreads (white, standard high fibre, or enzyme-150 
treated high fibre) within a 5 min period and further blood was collected at 1, 2, 3, 4, 5, 6 and 7 h 151 
and vascular measurements were conducted at 2, 5 and 7 h. Volunteers were provided with a low-152 
fat, low-polyphenol lunch (consisting of 2 slices of white bread, low fat cream cheese containing 153 
3% fat, lightly salted crisps and a low-fat vanilla yoghurt) at 3 h and had free access to bottled water 154 




experimental arm, participants followed a washout period of 14 days prior, where they were asked 156 
to follow their normal habitual diet, before switching to an alternate arm of the trial.  A qualified 157 
nurse was responsible for cannulation and blood collection.  All study personnel, including research 158 
nurses and research staff were blinded to the interventions. The study followed ethical standards, 159 
which were in accordance with the University of Reading Ethics Committee.  No changes were 160 
made to any of the trial methods or outcomes following the commencement of the trial.  161 
Recruitment for the trial took place between Oct 2012 and February 2013, whilst the trial was 162 
conducted between January 2013 and January 2014. 163 
Flow Mediated Dilatation (FMD) 164 
Subjects were positioned into the supine position with the right arm rested on a custom-made arm 165 
support at a 90º angle with their hand facing towards the ceiling. Electrocardiogram (ECG) pads 166 
were attached to time each image frame with respect to the cardiac cycle. A sphygmomanometric 167 
cuff was placed on the forearm and an image of the longitudinal brachial artery was obtained using 168 
a 3.5 x 1.0 cm hockey-stick probe, attached to a flexible holding device with locking action to allow 169 
for accurate measurements, and ATL Ultrasound HDI5000 broadband ultrasound system. The live 170 
image was captured using image-grabbing software (MIA-llc) and collected images at 0.25 171 
frames/second. A baseline measurement was recorded for 40 seconds using the flow. After this the 172 
main FMD measurement was started by recording the image for 60 seconds before arterial 173 
occlusion was created by inflating the cuff to 220mmHg causing ischemia of the arterial vessel. 174 
After 5 minutes the cuff was deflated, rapidly causing a decrease in pressure leading to reactive 175 
hyperemia to accommodate the dilated resistance levels. Image collection continued for 5 minutes 176 
post release and analysis of the arterial diameter was performed to assess the flexibility of the artery 177 
calculated as the relative diastolic diameter change from baseline compared to the peak diastolic 178 
diameter. Analysis was performed using a semi-automated computerized analysis system (Brachial 179 
Analyzer; Medical Imaging Applications-11c).  In order to avoid potential inter-individual, and 180 




conducted all FMD measurements.  Additionally, care was taken to conduct brachial artery flow-182 
mediated dilatation measurements consistently, with probe placements and cuff positioning 183 
carefully recorded and replicated between and across individuals. 184 
 185 
Laser Doppler Imaging with iontophoresis (LDI) 186 
The assessment of peripheral microvascular function [26,27] was conducted via the administration 187 
of an endothelial-dependent vasodilator, acetylcholine ACh (1%), and an endothelium in-dependent 188 
vasodilator, sodium nitroprusside (SNP) (1%), to the skin, which were delivered transdermally 189 
using iontophoresis. Subjects were rested in the supine position, with their right arm supported by 190 
an armrest. Two ION 6 chambers were applied to the forearm, within 1cm of each other, using 191 
double sided adhesive disks. 2.5ml of freshly prepared ACh (1% w/v in 0.5% (w/v) NaCl solution; 192 
Sigma Aldrich, Poole, Dorset, UK) was introduced to the anodal chamber and 2.5ml of SNP (1% 193 
w/v in 0.5% (w/v) NaCl solution; Sigma Aldrich, Poole, Dorset, UK) into the cathodal chamber. A 194 
coverslip was placed over each chamber to prevent any liquid from escaping. After baseline of skin 195 
perfusion was measured, an incremental electrical current was delivered simultaneously across the 196 
two chambers using the laser Doppler imager (LD12-VR) and MIC2 iontophoresis controller (Moor 197 
instruments Ltd) (increased in 5µA steps; 5, 10, 15 and 20 µA to yield a total charge of 8 198 
milliCoulombs within 12 minutes). A total of 20 scans were performed. An indicator of 199 
microvascular response due to ACh and SNP was calculated by the area under the flux versus time 200 
curve during the 20 scans.  201 
Digital Volume Pulse (DVP) 202 
The DVP stiffness index (DVP-SI) and DVP reflexion index (DVP-RI) was calculated by placing a 203 
PulseTrace PCA 2 with a photoplethysmograph transducer (MircoMedical, Kent) on the index 204 
finger of the left hand, transmitting an infrared light at 940nm. DVP was conducted as previously 205 
described [28-30]. The infrared light transmission through the finger records the systolic and 206 




(DVP-RI). The DVP-SI (in m/s) is related to large arterial stiffness and is measured by dividing the 208 
height of the subject by the time between the first and the second wave peaks of the DVP. It is 209 
related to CVD risk factors such as blood pressure, age and waist to hip ratio. The DVP-RI is 210 
related to smaller artery stiffness and is defined as the relative height of the second peak compared 211 
with the first.  212 
Plasma FA analysis 213 
Blood was collected at baseline and 1, 2, 3, 4, 5,6 and 7h after ingestion and processed as described 214 
in [31] and analyzed as follows.  LC-MS analysis, as described by [32], with minor modifications 215 
was also used to assess FA levels and other phenolic acids in human plasma samples.  Measurements 216 
were performed on an ABSciex 4000QTRAP MS system linked to an Agilent 1200 HPLC, column 217 
oven set to 30 °C, flow rate 200 μl/min. The column eluent was introduced into the mass spectrometer 218 
by a TurboIonSpray probe operating at 475 °C, with ion spray voltage set in negative mode to −4500 219 
V. Both the nebulizer gas pressure (GS1) and turbo heater gas (GS2) were set to 60 psi. The curtain 220 
gas flow was set to 25 l/min. The MS data were collected in MRM scan mode with compound-221 
dependent parameters.  222 
Data handling, power calculations and statistical analysis 223 
The power calculation was based on the primary clinical outcome measure (FMD of the brachial 224 
artery) in order to determine the minimum number of participants required for the study.  The 225 
minimal physiologically significant improvement on FMD measurable is an absolute change of 226 
between 1 to 2 % in FMD, considering a baseline vasodilatation of 4-6 %. The sample size was 227 
calculated based on the variance of repeated measurement in the control group and on control data.  228 
Consequently, with a standard deviation within patients of 2.3% (based on previous studies 229 
performed in our group), a significance level of 0.05 and a power of 80%, 18 subjects were required 230 
in order to determine a significant within-subject difference between treatments of at least 2.1%.  231 
Two-way repeated measured ANOVA was used to analyze all data using GraphPad Prism version 4 232 




multiple comparisons test. Significance was defined as P <0.05, with P values represented in the 234 
figures as * P = 0.01-0.05, ** P = 0.001-0.01, *** P = <0.001, ****P = <0.0001. The incremental 235 
area under the LDI flux versus time curve (IAUC) was calculated using the trapezoidal method. 236 
Prism (GraphPad software, USA) was used to analyze the data. Differences by treatment were 237 
identified using a two-way ANOVA with repeated measures. Post hoc analysis was subjected to 238 
Bonferroni correction. P values less than 0.05 were treated as significant. 239 
 240 
RESULTS 241 
Baseline measurements 242 
All baseline measurements of the subjects were within the normal range (Table 2) including blood 243 
pressure and FMD. All treatments were well tolerated, with only one participant withdrawing due to 244 
an adverse event (gastrointestinal discomfort on both high fibre interventions).  245 
 246 
Release of free FA from flatbreads 247 
The levels of free, conjugated and bound FA in the white and high fibre flatbreads are presented in  248 
Table 1.  Enzyme treatment of high fibre bread resulted in the release of more than 60 % of bound 249 
FA, with 30g of enzyme-treated high fibre flatbread providing 4.74 mg of free FA, compared to 250 
0.78 mg in standard high fibre and 0.16 mg in white bread.  Three flatbreads were provided per 251 
treatment, delivering a 22.21mg of total FA after consumption of the enzyme-treated high fibre 252 
flatbread, compared to 18.87mg from the non-enzyme treated high fibre flatbread and 1.38mg from 253 





Vascular function  256 
A time-dependent increase in FMD was observed following consumption of the enzyme-treated 257 
high fibre bread with significantly increased brachial arterial dilation at 2 h (p<0.05), 5 h (p<0.01) 258 
and 7 h (p<0.05), relative to the white bread and at 5 h (p<0.01), relative to non-treated high fibre 259 
control (n = 19) (Figure 2).  FMD increased by 0.9 ± 0.5% at 2 h, 1.5 ± 1.1% at 5 h and 1.2 ± 0.9% 260 
at 7 h for the enzyme-treated high fibre flatbread, relative to baseline.  No significant differences in 261 
FMD were observed at baseline between groups (p>0.05) or following intake of either the white 262 
bread or the non-treated high fibre bread, relative to baseline (p>0.05), although FMD levels were 263 
elevated following consumption of non-treated high fibre flatbread at 7 h (p = 0.098, n = 19).  264 
Blood pressure, heart rate, DVP-SI and DVP-RI were not significantly altered following the 265 
consumption of any of the breads (Table 2) or between baseline and post intervention (p>0.05; 2-266 
way ANOVA with Bonferroni post-hoc analysis).  Following consumption of the enzyme-treated 267 
high fibre bread, there was a rise in endothelium-dependent vasodilation (as indicated by increases 268 
in skin erythrocyte flux in the presence of acetylcholine chloride) at 5h and a return to baseline at 7h 269 
(Figure 3 (A)), although this was not statistically significantly. Similarly, no changes were 270 
observed in response to SNP (endothelium independent) for any of the treatments (Figure 3 (B)).  271 
 272 
Plasma ferulic acid analysis 273 
No significant increases in total plasma phenolic acids were observed over the 7 h period (Figure 274 
4(A)).  However, a significant increase in plasma ferulic acid was observed following intake of the 275 
enzyme-treated high fibre flatbread at 2 h (p<0.001) and 5 h (p<0.01), verses white bread and at 2 h 276 
(p<0.001) and 5 h (p<0.05), versus non-treated high fibre control (Figure 4 (B)). None of the other 277 
individual phenolic acids measured in the study differed between treatments (p < 0.05; 278 






In the present study, we show improved acute vascular function following the consumption of the 282 
high fibre flatbread which had been treated with an esterase enzyme to release FA bound to 283 
arabinoxylan fibre.  The release of FA during bread making resulted in a significantly higher level 284 
of ferulic acid reaching the circulation (relative to control breads) and resulted in a significant 285 
increase in FMD at 2 (p<0.05) and 5 h (p<0.01) compared to both the high fibre and white flatbread 286 
controls (Figure 2).  These results are in agreement with a study which showed that intake of wine 287 
containing a similar amount of phenolic acids improves endothelial-independent vasodilation 288 
acutely in healthy volunteers [33].  Furthermore, with respect to FMD effect size, our data are also 289 
in agreement with previous data sets showing increases in brachial artery dilation at 1-2 and 6 h 290 
following ingestion of, for example the equivalent of 240g fresh weight of blueberries (containing 291 
766-1791 mg of polyphenols) [34], cocoa [35, 36], red wine [37] and decaffeinated coffee [38]. 292 
 293 
The increase in FMD observed in response to the enzyme-treated high fibre flatbread was paralleled 294 
by an increase in plasma FA.  Previous studies have reported free FA concentrations in plasma of 295 
between 150-210 nM at 1 to 3 hours post consumption of a high bran cereal [39] and 296 
640µmol/min/L after consumption of bread [40], with these foods delivering phenolics primarily in 297 
the bound-form with no attempt to release FA prior to consumption. There is evidence that FA can 298 
be released from arabinoxylan via the action of microbiota-derived esterases and xylanases [21,41-299 
43], although this appears to be of limited efficiency, with only about 25% released by fecal 300 
esterases [21,44,45]. Previous work has also shown that processing (fermentation and enzyme 301 
treatment) of wheat bran can increase free FA in bread by up to 8-fold [46] and lead to increased 302 
release of FA in the colon, and consequently increases in derived metabolites such as 3,4-303 
dihydroxyphenylpropionic acid, 3-hydroxyphenylpropionic acid and 3-phenylpropionic acid.  Such 304 
bioprocessed bread has been shown to increase the bioavailability of phenolic acids and lead to 305 





With respect to mechanism of action, there are very few studies regarding the physiological actions 308 
of FA and its metabolites on endothelial function. Animal studies indicate the potential for FA to 309 
improve endothelium dysfunction in aortas of rats with spontaneous hypersensitivity [47], and in 310 
conjunction with astragaloside IV in streptozotocin-induced diabetic rats [48]. Both studies 311 
concluded that FA increased NO bioavailability via a decrease in NADPH-dependent superoxide 312 
anion levels [47] and by regulating eNOS activity [48].  In humans, the intake of oats, which is also 313 
rich in FA and other phenolics, has been shown to enhance the FMD response in overweight, 314 
dyslipidemic adults, particularly in post-menopausal women [49], providing further support for an 315 
NO-mediated mechanism.  In addition to such a pathway of activity, it has also been suggested that 316 
the intake of any cereal food rich in aleurone cells (which have high contents of fibre, phenolics and 317 
other potentially beneficial components) may also improve markers of immune function status, such 318 
as C-reactive protein and adhesion molecules [50]. Additional support for the causal activity of 319 
phenolic acids in vascular benefits, comes from the late improvement in FMD following 320 
consumption of the untreated high fibre bread, in the current study, where the excretion of total 321 
phenolic acids was highest.  Such metabolites include isoferulic acid, hippuric acid and 322 
protocatechuic acid, metabolites known to be products of hydroxycinnamic acids, after bacterial 323 
metabolism in the large intestine [51-53]. Similarly, small phenolic metabolites derived from 324 
anthocyanin and chlorogenic acid were proposed to mediate improvements in FMD at 6 h post-325 
consumption of blueberry flavonoids [33].  326 
 327 
Another potential mechanism may involve an increase in steady-state NO levels, via inhibition of 328 
NADPH oxidase. Ferulic acid may inhibit NADPH oxidase, in a similar manner to the structurally 329 
related drug apocynin, thus reducing superoxide levels.  This reduction in superoxide formation 330 
may maintain nitric oxide levels by limiting the reaction of nitric oxide with superoxide (to form 331 




NADPH oxidase activity by phenolic metabolites, such as FA and isoferulic acid, has been 333 
observed in clinical trials following intake of blueberry polyphenols, which occurred concurrently 334 
with an increase in FMD [33] and has been noted in cell studies with flavanols [54,55].  FA, and its 335 
metabolites, have structural homology to apocynin, a known NADPH oxidase inhibitor [56], with 336 
ferulic, vanillic, homovanillic, and hippuric acids, as well as tyrosol and hydroxytyrosol, all 337 
possessing significant inhibitory activity [55, 56] .  Further investigation is required to define the 338 
detailed mechanism by which wholegrain phenolics exert their activity in humans, however, it 339 
appears likely that the interactions of these small phenolics with the endothelium and its local 340 
environment may underpin such physiological events.  341 
In conclusion, this study has shown that enzymatic processing of high fibre bread can increase the 342 
bioavailability of FA and lead to improvements in human vascular function. Our data also suggest 343 
that the global influence of wholegrain intake on human cardiovascular health may also relate to the 344 
combined influence of both fibre and phenolic acids present within the wholegrain.  Further 345 
development of innovative baking and bread processing techniques, such as enzymatic treatment of 346 
dough to release potential bioactives, may represent a promising approach to improve the bio-347 
accessibility of these beneficial components of wholegrain in a cost-effective way to a wide section 348 
of the population.  349 
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1 Values are means ± SD. (n=19). 
 
  
Characteristic Value  
Age (yrs) 26.6 ± 6.4  
Height (m) 1.8 ± 0.1  
Weight (kg) 76.6 ± 11.7  
BMI (kg/m2 24.2 ± 2.4  




   Systolic 121.2 ± 10.8  
   Diastolic 70.3 ± 8.0  
Total cholesterol (mmol/l) 4.4 ± 0.8  
Glucose (mmol/l) 5.3 ± 0.4  
TAG (mmol/l) 0.8 ± 0.3  
Brachial artery diameter (mm) 4.1 ± 0.5  




Table 2.  
Compositional analysis of white, non-treated high fibre and enzyme-treated high fibre flatbreads.1 











White flour (%) 60.5 0.0 0 
High Fibre flour (%) 0.0 60.5 60.5 
Water (%) 34.8 34.8 34.8 
Ultraflo L ® activated (%) 0.0 0.0 3.9 
Ultraflo L ® de-activated (%) 3.9 3.9 0 
Salt (%) 0.8 0.8 0.8 
 
Energy (k joules) (kj/100g) 1169.0 1193.0 1247.0 
Energy (k calories) (kcal/100g) 276.0 282.0 294.0 
Protein (g/100g) 7.70 8.90 9.20 
Total Carbohydrate (g/100g) 60.60 61.10 63.00 
 Total sugars (g/100g) 3.30 4.00 3.70 
Fat (g/100g) 0.80 1.20 1.30 
 Saturates (g/100g) 0.14 0.24 0.26 
 Monounsaturates (g/100g) 1.23 0.24 0.18 
 Polyunsaturates (g/100g) 0.39 0.67 0.80 
 Trans fatty acids (g/100g) <0.1 <0.1 <0.1 
Total fibre (g/100g) 2.40 4.60 3.20 
Sodium (mg/100g) 315.00 320.00 315.00 
Moisture content (g/100g) 29.70 27.30 25.00 
Ash content (g/100g) 1.18 1.48 1.54 
Free FA (mg/100g)        0.53 2.60 15.80 
Conjugated FA (mg/100g)       0.01 1.47 0.33 
Bound FA (mg/100g)    1.00 16.90 9.43 
Total FA (mg/100g) 1.54 20.97 25.56 
1 Values based on freeze dried flatbread.  364 




Table 3.  Acute effects of interventions on blood pressure, heart rate and DVP.1 366 
 367 
  Baseline 2h 5h 7h 
Systolic blood pressure 
(mm Hg) 
    
White 124 ± 2 121 ± 2 120 ± 3 121 ± 2 
Non-Treated High Fibre 121 ± 2 120 ± 2 120 ± 2 121 ± 2 
Enzyme-Treated High Fibre  121 ± 2 121 ± 2 120 ± 2 120 ± 2 
Diastolic blood pressure 
(mm Hg) 
    
White 71 ± 1 68 ± 1 67 ± 1 72 ± 2 
Non-Treated High Fibre 73 ± 2 68 ± 1 68 ± 2 71 ± 2 
Enzyme-Treated High Fibre  71 ± 1 69 ± 1 67 ± 1 71 ± 1 
Heart rate (beats/min) 
    
White 56 ± 2 58 ± 2 59 ± 2 57 ± 2 
Non-Treated High Fibre 59 ± 2 60 ± 2 62 ± 2 59 ± 2 
Enzyme-Treated High Fibre  59 ± 2 61 ± 2 60 ± 2 60 ± 2 
DVP-SI (m/s) 
    
White 5.14 ±.8 5.3 ± 1 5.2 ± 1 5.6 ± 0.4 
Non-Treated High Fibre 5.2 ± 0.3 5.5 ± 0.4 5.5 ± 0.4 5.4 ± 0.5 
Enzyme-Treated High Fibre  5.5 ± 0.3 5.4 ± 0.4 5.5 ± 0.4 5.4 ± 0.4 
DVP-RI (%) 
    
White 67 ± 12 66.6 ± 13 60.7 ± 13 62.1 ± 10 
Non-Treated High Fibre 64.2 ± 15 63.9 ± 10 60.5 ± 11 60.5 ± 7 
Enzyme-Treated High Fibre  66.2 ± 12 62.7 ± 14 62.1 ± 14 61 ± 12 




Figure Legends. 368 
Figure 1. Consort Diagram. Flow diagram of the progress through the phases of the randomised 369 
clinical trial indicating participant numbers at enrolment, intervention allocation, follow-up, and 370 
data analysis. 371 
  372 
Figure 2. Time dependent changes in FMD (n=19, mean ± SD) following consumption of enzyme-373 
treated high fibre (), non-treated high fibre (◼) and white bread (⚫).  Data were analyzed using 2-374 
way ANOVA with post-hoc analysis conducted by using a Bonferroni multiple-comparisons test. 375 
Levels of significance between samples are indicated as follows: enzyme-treated high fibre 376 
flatbread verses white flatbread; 2 h (* p < 0.05), 5 h (** p < 0.01) and 7 h (* p < 0.05) and enzyme-377 
treated high fibre flatbread vs non-treated high fibre flatbread 5 h (b: p < 0.01). 378 
  379 
Figure 3. Response of forearm skin erythrocyte flux following the iontophoresis of (A) 380 
acetylcholine chloride and (B) sodium nitroprusside (n=19) after consumption of white (⚫), non-381 
treated high fibre (◼) and enzyme-treated high fibre () flatbread. Values are means ± SEM.  382 
 383 
Figure 4.  (A). Total phenolic acids, in plasma at baseline, 2, 5 and 7 h following consumption of 384 
white (⚫), non-treated high fibre (◼) and enzyme-treated high fibre () flatbread (n=18; mean ± 385 
SEM).  (B). Concentration of free FA in plasma at baseline, 2, 5 and 7 h following consumption of 386 
white (⚫), non-treated high fibre (◼) and enzyme-treated high fibre () flatbread (n=18; mean ± 387 
SEM). Data were measured using 2-factor repeated measures ANOVA with time and treatment as 388 
the 2 factors. Post hoc analysis was conducted using a Bonferroni multiple comparisons test. a: 389 
white vs enzyme-treated high fibre, p <0.001; b: white vs enzyme-treated high fibre, p<0.01; c: non-390 
treated high fibre vs enzyme treated high fibre, p<0.001; d: non-treated high fibre vs enzyme-391 
treated high fibre, p<0.5. 392 
 
